OBJECTIVE: This study presents real-life experience with cefiderocol used on a compassionate basis for treatment of three patients with severe infections caused by extensively/pan-drug resistant (XDR/PDR) Acinetobacter baumannii (Ab). METHODS: Serum bactericidal activity was determined and considered as a surrogate of cefiderocol susceptibility. RESULTS: Clinical improvement and microbiological eradication of A. baumannii were observed in all three patients, who were affected by extremely complex conditions either for type of infection, adverse effect or resistance profile of A. baumannii. CONCLUSION: Cefiderocol for XDR/PDR-Ab infections might be reconsidered, especially in light of the recent disappointing results of the CREDIBLE-CR study.
OBJECTIVE: This study presents real-life experience with cefiderocol used on a compassionate basis for treatment of three patients with severe infections caused by extensively/pan-drug resistant (XDR/PDR) Acinetobacter baumannii (Ab). METHODS: Serum bactericidal activity was determined and considered as a surrogate of cefiderocol susceptibility. RESULTS: Clinical improvement and microbiological eradication of A. baumannii were observed in all three patients, who were affected by extremely complex conditions either for type of infection, adverse effect or resistance profile of A. baumannii. CONCLUSION:Cefiderocol for XDR/PDR-Ab infections might be reconsidered, especially in light of the recent disappointing results of the CREDIBLE-CR study.
Authors: Susannah L McKay; Nicholas Vlachos; Jonathan B Daniels; Valerie S Albrecht; Valerie A Stevens; J Kamile Rasheed; J Kristie Johnson; Joseph D Lutgring; Maria Sjölund-Karlsson; Alison Laufer Halpin Journal: Microb Drug Resist Date: 2022-05-27 Impact factor: 2.706
Authors: Massimiliano De Angelis; Maria T Mascellino; Maria C Miele; Dania Al Ismail; Marisa Colone; Annarita Stringaro; Vincenzo Vullo; Mario Venditti; Claudio M Mastroianni; Alessandra Oliva Journal: Antibiotics (Basel) Date: 2022-02-10